Rafał Derlacz

Rafał is Innovation Director at Rezon Bio, a science-driven contract development and manufacturing organization (CDMO) grounded in Polpharma Biologic’s legacy of excellence in biosimilars. Rezon Bio specializes in the development and manufacturing of mammalian biologics. In the past, Rafał was responsible for natalizumab biosimilar project, 1st biosimilar monoclonal antibody developed in Poland from cell line design to dossier registration of the final product by EMA and FDA. Currently, he is involved in the evaluation and implementation of new digital and technical solutions to optimize development and manufacturing of biologics.